Telsey Advisory lowered the firm’s price target on Waldencast (WALD) to $3 from $4 and keeps an Outperform rating on the shares. The moderated annual outlook comes as a disappointment as solid underlying trends are offset by softening international consumption, out of stocks at its brands, and exiting of non-core distribution points at Obagi, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast price target lowered to $2 from $2.40 at TD Cowen
- Waldencast Reports Strong H1 2025 Growth and Strategic Initiatives
- Waldencast Acquisition Corp. (WALD) Q2 Earnings Cheat Sheet
- Waldencast Acquires Novaestiq and U.S. Rights to Saypha®
- Waldencast acquires Novaestiq Corp., rights to Saypha gels